Related Experiment Video
Updated: Jun 15, 2026
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
Published on: July 25, 2025
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
Daoyan Wei1, Liang Wang2, Yi Liu3
1Departments of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by late diagnosis, early metastasis, and resistance to conventional therapies. A major barrier to effective treatment is its desmoplastic and immunosuppressive tumor microenvironment, which restricts T-cell infiltration and dampens responses to immune checkpoint inhibitors (ICI). These features highlight the urgent need for innovative immunotherapeutic strategies capable of overcoming PDAC's immunologic and physical barriers. Chimeric antigen receptor (CAR)-macrophage (CAR-M) therapy has emerged as a promising approach to address these challenges. Unlike CAR-T or CAR-NK cells, CAR-Ms can efficiently infiltrate tumors, remodel the tumor microenvironment, phagocytose tumor cells, and stimulate adaptive immunity. This review highlights recent advances in CAR-M therapy for solid tumors, with an emphasis on PDAC. Preclinical studies show that CAR-Ms enhance antigen presentation, secrete proinflammatory cytokines, and recruit cytotoxic T cells, thereby amplifying antitumor responses. Progress in CAR-M engineering-such as dual-targeting strategies, CRISPR-based modifications, and combinations with ICIs or other therapies-further strengthens their therapeutic potential. Importantly, early-phase clinical trials in solid tumors support the safety, tolerability, and tumor-modulating capacity of CAR-Ms, laying the groundwork for their application in PDAC. To fully harness CAR-M therapy in PDAC, several challenges must be addressed, including improving CAR-M persistence and efficacy, optimizing tumor-specific targeting, developing scalable and cost-effective manufacturing platforms, and integrating strategic combinations with other therapies, such as ICIs and KRAS inhibitors. With continued innovation and clinical validation, CAR-M therapy has the potential to transform PDAC treatment, fulfill critical unmet clinical needs, and provide new hope for patients.
Insights
Chimeric antigen receptor-macrophage (CAR-M) therapy shows promise for pancreatic cancer by overcoming the tumor microenvironment. CAR-Ms infiltrate tumors, enhance immune responses, and offer new hope for patients resistant to current treatments.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents significant treatment challenges due to its immunosuppressive tumor microenvironment (TME).
- Existing therapies, including immune checkpoint inhibitors (ICIs), are often limited by the TME's physical and immunological barriers, hindering T cell infiltration and efficacy.
- There is a critical need for novel immunotherapeutic strategies to overcome these barriers in PDAC.
Purpose of the Study:
- To review recent advancements in Chimeric antigen receptor-macrophage (CAR-M) therapy for solid tumors, focusing on its potential application in PDAC.
- To highlight the unique advantages of CAR-Ms, such as tumor infiltration and TME modulation, compared to other CAR-based therapies.
- To discuss the progress in CAR-M engineering and early clinical trial findings, as well as challenges and future directions for PDAC treatment.
Main Methods:
- Review of preclinical and early-phase clinical studies on CAR-M therapy in solid tumors.
- Analysis of CAR-M mechanisms of action, including antigen presentation, cytokine secretion, and immune cell recruitment.
- Examination of CAR-M engineering strategies and combination therapies.
Main Results:
- Preclinical data demonstrate that CAR-Ms can remodel the TME, enhance antigen presentation, and stimulate anti-tumor adaptive immunity.
- CAR-M therapy shows potential to overcome resistance to ICIs by improving T cell function and infiltration.
- Early clinical trials indicate CAR-Ms are safe, tolerable, and possess tumor-modulating capabilities in solid tumors.
Conclusions:
- CAR-M therapy represents a promising innovative approach to overcome the challenges posed by the PDAC tumor microenvironment.
- Further research and clinical validation are needed to optimize CAR-M persistence, efficacy, targeting, manufacturing, and combination strategies for PDAC.
- CAR-M therapy holds significant potential to transform PDAC treatment and address unmet clinical needs.
